Apple Faces Margin Pressure as Memory Chip Prices Surge Amid AI Boom 
Saks Global to End Saks on Amazon Partnership Amid Bankruptcy Restructuring 
Elon Musk’s Empire: SpaceX, Tesla, and xAI Merger Talks Spark Investor Debate 
SoftBank and Intel Partner to Develop Next-Generation Memory Chips for AI Data Centers 
CSPC Pharma and AstraZeneca Forge Multibillion-Dollar Partnership to Develop Long-Acting Peptide Drugs 
SpaceX Updates Starlink Privacy Policy to Allow AI Training as xAI Merger Talks and IPO Loom 
Sam Altman Reaffirms OpenAI’s Long-Term Commitment to NVIDIA Amid Chip Report 
Using the Economic Calendar to Reduce Surprise Driven Losses in Forex 
Hyundai Motor Lets Russia Plant Buyback Option Expire Amid Ongoing Ukraine War 
Jensen Huang Urges Taiwan Suppliers to Boost AI Chip Production Amid Surging Demand 
Panama Supreme Court Voids CK Hutchison Port Concessions, Raising Geopolitical and Trade Concerns 
Federal Judge Signals Possible Dismissal of xAI Lawsuit Against OpenAI 
Panama Supreme Court Voids Hong Kong Firm’s Panama Canal Port Contracts Over Constitutional Violations 
SpaceX Seeks FCC Approval for Massive Solar-Powered Satellite Network to Support AI Data Centers 
Boeing Secures New Labor Contract With Former Spirit AeroSystems Employees 
SAN FRANCISCO, May 30, 2017 -- ProLynx LLC today announced that the United States Patent and Trademark Office has issued US Patent 9,649,385 entitled “Hydrogels with Biodegradable Crosslinking”. The patent broadly covers the use of ProLynx’s ß-eliminative linkers to control the in vivo bio-degradation rate of hydrogels used for drug delivery. Previously, patents were issued on the use of these linkers to control release of drugs tethered to these hydrogel carriers.
The recently issued patent is part of a growing intellectual property portfolio that now includes six issued US patents and five pending US applications, along with 11 issued ex-US patents and corresponding international applications. These patents and applications cover ProLynx proprietary linkers and their use in various applications, including soluble and insoluble conjugates generally as well as specific examples of the technology.
"This patent is an important component of ProLynx's intellectual property portfolio since it extends the utility of our beta-eliminative linkers to controlling the in vivo residence times of our hydrogel microsphere drug carriers," said co-founder and President Daniel V. Santi, M.D., Ph.D. "The technology allows us to balance the rates of drug release and carrier degradation such that after the drug is released, the carrier dissipates, dissolves and eliminates."
About ProLynx.
ProLynx LLC is a privately held biotechnology company developing proprietary drug delivery systems for half-life extension of proteins, peptides and small molecules. The company is seeking to apply its technology to extend half-lives of drug candidates of pharmaceutical companies, and to improve properties of off-patent therapeutics. ProLynx has a monthly GLP-1 receptor agonist and a subcutaneous long-acting octreotide in its pre-clinical portfolio, and a PEG~SN-38 in Phase 1 clinical trials. The company is located in San Francisco, CA. Further information about the company and its capabilities may be found at http://www.prolynxllc.com.
Contact: Usha Arunachalam: [email protected] Eric Schneider: [email protected] 415-552-5306
